NEW YORK (GenomeWeb News) – MDxHealth said today that revenues in the third quarter rose 145 percent year over year, driven by a 141 percent increase in commercial revenues.

For the three months ended Sept. 30, MDxHealth's total revenues increased to €925,000 ($1.2 million) from €378,000 a year ago, as its commercial revenues climbed to €644,000 from €267,000.

The firm, based in Liege, Belgium, and with offices in Irvine, Calif., did not disclose its expenses for the third quarter. Its net loss for the period increased to €2.3 million from €1.9 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.